Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs placebo as adjuvant therapy in high-risk locally advanced head and neck squamous cell carcinoma
CTR20180739Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Roche. Started Jul 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20180739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180739.